New York, May 4 (AP) Pfizer, buoyed by a huge jump in sales for its COVID-19 vaccine and solid performance across most of the company, is hiking its 2021 financial forecast sharply after blowing past Wall Street expectations for the first quarter.

The New York drugmaker and its German partner on the vaccine, BioNTech, continue to sign contracts with multiple countries for their two-dose shot.

They reported USD 3.46 billion in first-quarter sales and now expect to rake in roughly USD 26 billion over the year, up from their prior forecast of about USD 15 billion.

The companies may soon receive U.S. and EU approval to give the vaccine to 12- through 15-year-olds and continue testing the vaccine in other patient groups, including pregnant women and children from six months to 11 years old.

The partners are also testing the efficacy of a booster shot of the vaccine, which may be needed — perhaps annually — to keep immunity high over time and to protect people from numerous emerging coronavirus variants that may spread more easily or be more deadly.

And they're developing new vaccine versions that have a longer shelf life and don't require being kept frozen.

Pfizer on Tuesday reported net income of USD 4.88 billion, or 86 cents per share.

That was up from USD 3.36 billion, or 60 cents per share, in 2020's first quarter, when the global coronavirus pandemic began triggering lockdowns, and doctor visits and new prescriptions for other medicines dropped significantly.

Adjusted earnings, excluding one-time items, jumped 48 per cent to USD 5.26 billion, or 93 cents per share, far above the 79 cents Wall Street was expecting, according to a survey by Zacks Investment Research.

Revenue was USD 14.58 billion, also easily exceeding forecasts of USD 13.49 billion.

The maker of the blockbuster Prevnar vaccine against pneumococcal disease said even without COVID-19 vaccine sales, it is meeting its goal of increasing revenue by at least 6 per cent each year through 2025.

“Excluding the growth provided from (the vaccine), our revenues grew 8 per cent operationally,” Chief Executive Albert Bourla said in a prepared statement, adding, "In addition, we have achieved important clinical, regulatory and commercial milestones across our pipeline and portfolio while also continuing to increase our capacity to supply urgently-needed doses" of the COVID-19 vaccine."

Pfizer now expects to be able to deliver about 2.5 billion vaccine doses this year and already has signed contracts covering about 1.6 billion of those doses, including 200 million doses promised for the U.S. by the end of May and another 100 million doses later this year.

The company also has begun testing a pill to treat COVID-19.

Meanwhile, sales of cancer drugs jumped 18per cent in the quarter and sales of medicines administered in hospitals rebounded 11per cent as patients got treatments delayed by hesitance to go to hospitals swamped with COVID-19 patients. Sales of clot preventer Eliquis jumped 26per cent to USD1.64 billion.

During the quarter, the U.S. Food and Drug Administration approved an additional use for Pfizer's immunoglobulin drug Panzyga, for treating a rare condition that damages peripheral nerves. The FDA also approved use of the company's Lorbrena as an initial treatment for non-small cell one cancer.

Pfizer noted the FDA is now reviewing its application for its experimental vaccine against tick-borne encephalitis, for people as young as age 1.

And while an updated version of its vaccine against pneumococcal disease awaits regulatory approval, Pfizer has begun testing the safety of administering that vaccine at the same time as a COVID-19 vaccine booster.

Pfizer now expects full-year earnings in the range of USD3.55 to USD3.65 per share, up from USD3.10 to USD3.20 per share in February, and revenue in the range of USD70.5 billion to USD72.5 billion, up from USD59.4 billion to USD61.4 billion in the February forecast.

In premarket trading, Pfizer shares rose 31 cents to USD40.15. (AP)

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)